Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia
- PMID: 31345068
- PMCID: PMC6934043
- DOI: 10.1080/02656736.2019.1631494
Increased uptake of doxorubicin by cells undergoing heat stress does not explain its synergistic cytotoxicity with hyperthermia
Abstract
Purpose: A proposed mechanism for the enhanced effectiveness of hyperthermia and doxorubicin (Dox) combinations is increased intracellular Dox concentrations resulting from heat-induced cell stress. The purpose of this study was to determine whether specific varied Dox and heat combinations produce measurable effects greater than the additive combination, and whether these effects can be attributed to heat-induced increases in intracellular Dox concentrations. Methods: HCT116, HT29 and CT26 cells were exposed to Dox and water bath heating independently. A clonogenic survival assay was used to determine cell killing and intracellular Dox concentrations were measured in HCT116 cells with mass spectrometry. Cells were exposed to heating at 42 °C (60 min) and 0.5 µg/ml of Dox at varying intervals. Synergy was determined by curve-fitting and isobologram analysis. Results: All cell lines displayed synergistic effects of combined heating and Dox. A maximum synergistic effect was achieved with simultaneous cell exposure to Dox and heat. For exposures at 42 °C, the synergistic effect was most pronounced at Dox concentrations <0.5 µg/ml. Increased intracellular concentrations of Dox in HCT116 cells caused by heat-stress did not generate a concomitant thermal enhancement. Conclusions: Simultaneous exposure of HCT116 cells to heating and Dox is more effective than sequential exposure. Heat-induced cell responses are accompanied by increased intracellular Dox concentrations; however, clonogenic survival data do not support this as the cause for synergistic cytotoxicity.
Keywords: Hyperthermia; chemotherapy; colorectal cancer; doxorubicin; thermal dose.
Conflict of interest statement
Disclosure statement
R.I. and E.L. are inventors on nanoparticle patents. All patents are assigned to either The Johns Hopkins University or Aduro BioTech, Inc. R.I. consults for Imagion Biosystems, a company developing imaging with magnetic iron oxide nanoparticles. All other authors report no conflicts of interest. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS or NIH.
Figures
Comment in
-
Time interval after heat stress plays an important role in the combination therapy of hyperthermia and cancer chemotherapy agents.Int J Hyperthermia. 2020;37(1):254-255. doi: 10.1080/02656736.2020.1736343. Int J Hyperthermia. 2020. PMID: 32157930 No abstract available.
-
For HIPEC, synergistic effects of hyperthermia and doxorubicin are optimal when simultaneously combined.Int J Hyperthermia. 2020;37(1):346-348. doi: 10.1080/02656736.2020.1750714. Int J Hyperthermia. 2020. PMID: 32270728 No abstract available.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: Cancer J Clin. 2016;66:7–30. - PubMed
-
- Murphy GP, Lawrence W, Lenhard RE. 1995. American Cancer Society Textbook of Clinical Oncology. 2nd ed. Atlanta, GA: The American Cancer Society.
-
- Banerjee A, Pathak S, Vasan D, et al. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today. 2017;22:1224–1232. - PubMed
-
- Kim S, Kim JH. Lethal effect of adriamycin on the division cycle of HeLa cells. Cancer Res. 1972;32:323–325. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources